Wave Life Sciences (WVE) Q1 2025 earnings summary

Executive summary

• Advanced clinical pipeline in obesity, AATD, DMD, and HD, leveraging proprietary oligonucleotide chemistries, RNA editing technologies, and the PRISM platform, with preclinical programs in Rett syndrome and cystic fibrosis.

• Achieved key milestones: first 48-week FORWARD-53 results for DMD, progress in INHBE/INLIGHT (obesity) and AATD trials, and positive regulatory interactions, including FDA support for accelerated approval in DMD.

• No product revenue to date; operations funded by equity offerings, collaborations (notably GSK), and private placements; Takeda collaboration expired in October 2024.

• Multiple data readouts and regulatory filings planned for 2025 and 2026, including NDA submission for DMD and phase 2-3 trial for HD.

• Cash and cash equivalents of $243.1M as of March 31, 2025, with runway into 2027.

Financial highlights

• Q1 2025 revenue was $9.2M, down from $12.5M year-over-year, reflecting lower GSK collaboration revenue and no Takeda revenue.

• R&D expenses rose to $40.6M (from $33.4M), driven by pipeline advancement and compensation.

• G&A expenses increased to $18.4M (from $13.5M), mainly due to share-based compensation and professional fees.

• Net loss widened to $46.9M from $31.6M year-over-year.

• Cash and equivalents decreased from $302.1M at year-end 2024 to $243.1M at March 31, 2025.

Outlook and guidance

• Initial INHBE/INLIGHT clinical data (safety, tolerability, weight loss, biomarkers) expected in H2 2025.

• Comprehensive AATD (WVE-006) multi-dose and single-dose data readouts planned for Q3 and fall 2025.

• NDA submission for DMD (N531) targeted for 2026, with monthly dosing regimen.

• Phase 2-3 global trial for HD (WVE-003) to begin in H2 2025, using caudate atrophy as primary endpoint; IND submission planned for 2H 2025.

• Clinical development of new pipeline programs anticipated in 2026.